These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22036303)

  • 21. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
    Tompkins CNE; Neale J; Strang J
    J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.
    Moratti E; Kashanpour H; Lombardelli T; Maisto M
    Clin Drug Investig; 2010; 30 Suppl 1():3-11. PubMed ID: 20450240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Sub is a weird drug:" A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms.
    Daniulaityte R; Carlson R; Brigham G; Cameron D; Sheth A
    Am J Addict; 2015 Aug; 24(5):403-9. PubMed ID: 26009867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of, and Factors Associated With, Illicit Pharmaceutical Opioid Analgesic Use in a Prospective Cohort of People Who Inject Drugs in Melbourne, Australia.
    Horyniak D; Agius PA; Degenhardt L; Reddel S; Higgs P; Aitken C; Stoové M; Dietze P
    Subst Use Misuse; 2015; 50(13):1650-9. PubMed ID: 26576630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy.
    Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Edwards RR; Samet JH
    Drug Alcohol Depend; 2016 Sep; 166():26-31. PubMed ID: 27422763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type of opioids injected: does it matter? A multicentric cross-sectional study of people who inject drugs.
    Ambekar A; Rao R; Mishra AK; Agrawal A
    Drug Alcohol Rev; 2015 Jan; 34(1):97-104. PubMed ID: 25302827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
    D'Onofrio G; O'Connor PG; Pantalon MV; Chawarski MC; Busch SH; Owens PH; Bernstein SL; Fiellin DA
    JAMA; 2015 Apr; 313(16):1636-44. PubMed ID: 25919527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma.
    Allen B; Harocopos A
    J Subst Abuse Treat; 2016 Nov; 70():81-86. PubMed ID: 27692193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
    Kaur AD; McQueen A; Jan S
    J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
    Johnson B; Richert T
    Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.
    Zhu Y; Evans EA; Mooney LJ; Saxon AJ; Kelleghan A; Yoo C; Hser YI
    J Neuroimmune Pharmacol; 2018 Dec; 13(4):488-497. PubMed ID: 30094695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers.
    Schuman-Olivier Z; Albanese M; Nelson SE; Roland L; Puopolo F; Klinker L; Shaffer HJ
    J Subst Abuse Treat; 2010 Jul; 39(1):41-50. PubMed ID: 20434868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids.
    Peacock A; Bruno R; Cama E; Kihas I; Larance B; Lintzeris N; Hordern A; White N; Ali R; Degenhardt L
    Drug Alcohol Rev; 2015 Nov; 34(6):611-22. PubMed ID: 26084592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of an interactive voice response system for daily monitoring of illicit opioid use during buprenorphine treatment.
    Parker MA; Ochalek TA; Rose GL; Badger GJ; Sigmon SC
    Psychol Addict Behav; 2018 Dec; 32(8):956-960. PubMed ID: 30359047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.
    Smith KE; Tillson MD; Staton M; Winston EM
    Drug Alcohol Depend; 2020 Mar; 208():107837. PubMed ID: 31951906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.